• About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • CD30 CAR-T Cell Therapy
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • Manufacturing
  • Pipeline
    • TT11 CD30 CAR Ts
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

What are you looking for?

Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
  • About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • CD30 CAR-T Cell Therapy
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • Manufacturing
  • Pipeline
    • TT11 CD30 CAR Ts
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us
    Category Archives

    PR 2020

  • All
    • home-featured
    • news-pressrelease
    • PR 2020

    Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer

    Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over…

    Continue Reading
    • home-featured
    • news-pressrelease
    • PR 2020

    Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

    Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology from…

    Continue Reading
    • home-featured
    • news-pressrelease
    • PR 2020

    Tessa Therapeutics Announces New Executive Leadership

    Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive…

    Continue Reading
    • home-featured
    • news-pressrelease
    • PR 2020

    Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

    RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by…

    Continue Reading
  • ABOUT US
  • TECHNOLOGY
  • PIPELINE
  • PRESS RELEASES & EVENTS
  • CAREERS
  • CONTACT US

SITEMAP          PRIVACY POLICY

© 2021 Tessa Therapeutics Ltd. All rights reserved.